Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

XOMA Corporation

http://www.xoma.com

Latest From XOMA Corporation

'Future Fit' Cipla: Play In Oligonucleotides, Obesity Amid Promoter Stake Action

Cipla is stepping into the oligonucleotides space, where it also hopes to help shape the regulatory environment. Action is also anticipated in ‘big, identified areas’ such as obesity that may see potential partnering opportunities with Eli Lilly, with which the Indian firm has an existing alliance for diabetes therapies.

Strategy Generic Drugs

'Future Fit' Cipla: Play In Oligonucleotides, Obesity Amid Promoter Stake Action

Cipla is stepping into the oligonucleotides space, where it also hopes to help shape the regulatory environment. Action is also anticipated in ‘big, identified areas’ such as obesity that may see potential partnering opportunities with Eli Lilly, with which the Indian firm has an existing alliance for diabetes therapies.

Commercial M & A

Lupin CEO Highlights Structural Support For Generics Pricing, Sees gMyrbetriq Relaunch

Lupin’s CEO spoke of US drug shortages having led to recognition of the need for structural and regulatory support for viable pricing of generic drugs. She was also optimistic on the relaunch of a Myrbetriq generic after Astellas obtained a temporary restraining order against Lupin and Zydus just a few days post an at-risk launch by the latter two companies

Commercial Sales & Earnings

Ipsen Dives Back Into Dealmaking With First ADC Pact

The French drugmaker has teamed up with South San Francisco's Sutro Biophgarma to bag the rights to a preclinical-stage ADC targeting ROR1.

Oncology Deals
See All

Company Information

  • Industry
  • Miscellaneous
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Enumeral Biomedical Inc.
    • XOMA Ltd.
UsernamePublicRestriction

Register